EP1687273A1 - Process for preparation of chiral amlodipine salts - Google Patents

Process for preparation of chiral amlodipine salts

Info

Publication number
EP1687273A1
EP1687273A1 EP04791865A EP04791865A EP1687273A1 EP 1687273 A1 EP1687273 A1 EP 1687273A1 EP 04791865 A EP04791865 A EP 04791865A EP 04791865 A EP04791865 A EP 04791865A EP 1687273 A1 EP1687273 A1 EP 1687273A1
Authority
EP
European Patent Office
Prior art keywords
amlodipine
acid
salt
formula
tartarate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04791865A
Other languages
German (de)
French (fr)
Inventor
Rohini Ramesh National Chemical Labor. JOSHI
Ramesh Anna National Chemical Labor. JOSHI
Nilesh Bapurao National Chemical Labor. KARADE
Mukund Keshav National Chemical Labor. GURJAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Council of Scientific and Industrial Research CSIR
Original Assignee
Council of Scientific and Industrial Research CSIR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council of Scientific and Industrial Research CSIR filed Critical Council of Scientific and Industrial Research CSIR
Publication of EP1687273A1 publication Critical patent/EP1687273A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Definitions

  • (R, S) amlodipine and its salts are long acting calcium channel blockers and are useful for the treatment of cardiovascular disorders. Racemic amlodipine is currently being used for the treatment of hypertension and angina as a besylate salt. The preparation of racemic compound is described in EP 0089167. Amlodipine is racemic compound and has chiral center at 4 position of dihydropyridine ring. The S(-) isomer is having calcium channel blocker activity while R(+) isomer is a potent inhibitor of smooth muscle cell migration.
  • Prior arts herein for the preparation of R and S enantiomers are a) resolution of amlodipine azide ester with optically active 2-methoxy-2-phenylethanol (J. Med. Chem.
  • the object of present invention is to provide a process for the preparation of S(-) and R(+) Amlodipine besylate frpom racemic amlodipine using D or L tartaric acid without isolating free amlodipine base Summary of the invention Accordingly, the present invention provides an improved process for the preparation of pharmaceutically acceptable chiral salts of Amlodipine namely S(-) Amlodipine salts having formula (1) and R(+) Amlodipine salts having formula (2)
  • R is selected from the group consisting of benzenesulpho ⁇ nic acid, succinic acid, maleic acid, oxalic acid and p-toluenesulphonicacid, wherein the salts of formula 1 and 2 are prepared without isolation of a free base with optical purity ranging between 96-99% the process comprising: (a) reacting a solution of RS amlodipine base in an organic solvent with a solution of L(+) or D(-) tartaric acid in an organic solvent at temperature ranging from 20-35°C for a period ranging between 16-24 hrs., to obtain a solvate comprising an amlodipine tartarate salt;
  • step (b) separating and reacting the amlodipine tartarate salt obtained in step (a) with an aqueous solution of an acid optionally in presence of an organic solvent, and at a temperature ranging between 20-40°C;
  • step (c) adding water to the reaction mixture of step (b) to obtain the salt of formula 1 or 2, separating the salt of formula 1 or 2 and drying to obtain salt corresponding to the acid used in step (2) with ee ranging from 96-99%.
  • the solvent used in step (a) is DMSO.
  • the concentration of RS amlodipine base to solvent (DMSO) ranges between 0.16 to 0.40 gm/ml.
  • L(+)-tartaric acid or D(-) tartaric acid employed is 0.25 mole equivalent of the amlodipine base.
  • the solvate obtained in step (a) is a precipitate comprising S(-) Amlodipine hemi D(-) tartarate mono DMSO solvate or R(+) amlodipine hemi L(+) tartarate mono DMSO solvate.
  • the solvent used for salt formation in step (b) is selected from dimethylsulfoxide, isopropylacohol and ethanol.
  • the ratio of water to solvent cumulatively taken in steps (b) and (c) ranges between 5: 1 to 8: 1.
  • the acid used in step (b) is selected from the group consisting of benzenesulfonic, maleic, oxalic acid and p-toluene sulfonic acid.
  • the ratio of amlodipine tartarate salt to organic solvent in step (b) is in the range 1 : 1 to 1 : 5.
  • the mole equivalent of benzene sulfonic acid used ranges between 0.9 to 1.
  • the optical purity of R(+) amlodipine besylate or S(-) amlodipine besylate is improved from 95% to 99% .
  • the present invention provides a process for the preparation of pharmaceutically acceptable chiral Amlodipine salts comprising S(-) Amlodipine salts having formula (1) and R(+) Amlodipine salts having formula (2)
  • R is selected from the group consisting of benzenesulphoinic acid, succinic acid, maleic acid, oxalic acid and p-toluene sulphonic acid.
  • the salts of formula 1 and 2 are prepared without isolation of a free base with optical purity ranging between 96-99%.
  • the process of the invention comprises of
  • step (b) separating the tartarate salt as obtained in step (a) and reacting the said salt with an aqueous solution of an acid optionally in presence of an organic solvent at a temperature ranging between 20-40°C.
  • step (c) adding water to the reaction mixture as obtained in step (b) to obtain the salt, separating the salt and drying to obtain salt corresponding to the acid used in step (b) with ee ranging from 96-99%.
  • the solvent used in step (a) above is preferably dimethyl sulfoxide (DMSO) and the concentration of the RS amlodipine base to solvent (DMSO) ranges between 0.16 to 0.40 gm/ml.
  • the L(+)-tartaric acid or D(-) tartaric acid employed in step (a) is 0.25 mole equivalent of the base.
  • the tartarate salt is obtained preferably by precipitation and the solvate precipitated is S(-) Amlodipine hemi D(-) tartarate mono DMSO solvate or R(+) amlodipine hemi L(+) tartarate mono DMSO solvate.
  • the solvent used for salt formation in step (b) is selected from dimethylsulfoxide, isopropylacohol or ethanol.
  • the ratio of amlodipine salt to organic solvent in step (b) is in the range 1:1 to 1:5 for salt formation.
  • the ratio of water to solvent cumulatively taken in steps (b) and (c) ranges between 5:1 to 8:1.
  • the acid used in step (b) is selected from benzenesulfonic acid, maleic acid, oxalic acid, and p-toluene sulfonic acid.
  • the mole equivalent of benzene sulfonic acid used ranges between 0.9 to 1.
  • the optical purity of R(+) amlodipine besylate or S(-) amlodipine besylate is improved from 95% to 99%
  • the unique feature of the invention is production pf S(-) Amlodipine or R(+) amlodipine salts with high enantiomeric purity, in good yields (87-92%) with the quality required for preparation of pharmaceutical composition i.e. tablet formulation.
  • the process of resolution of R,S amlodipine and besylate formation is shown in the scheme below:
  • Example 2 R(+)AmIodipine hemiL(+) tartarate mono DMSO solvate from RS amlodipine To a stirred solution of lOOgm (0.245 moles) of RS amlodipine in 300ml DMSO was added a solution of 9.2 gm (0.06 moles, 0.25 eq) of L(+) tartaric acid in 300 ml DMSO. The solid starts separating from clear solution within 5-10 mins.
  • Example 3 R(+)Amlodipine hemiL(+)tartarate mono DMSO solvate from RS amlodipine
  • lOOgm 0.245 moles
  • RS amlodipine 150ml DMSO
  • 9.2gm 9.2gm (0.06 moles, 0.25 eq)
  • L (+) tartaric acid 100 ml DMSO.
  • the solid starts separating from clear solution within 5-10 mins. This was stirred for 3 hrs and solid was filtered off, washed with acetone and dried to give 58.6gm (40.5%) R (+) amlodipine hemi L(+) tartarate mono DMSO solvate.
  • Example 4 S(-)amIodipine hemi D(-)tartarate mono DMSO solvate from RS amlodipine To a stirred solution of lOOgm (0.245 moles) of RS amlodipine in 500ml DMSO was added a solution of 9.2 gm (0.06 moles, 0.25 eq) of D(-) tartaric acid in 500 ml DMSO. The sohd starts separating from clear solution within 5-10 mins. This was stirred at room temperature overnight and sohd was filtered off, washed with acetone and dried to give 47.5gm (34.6%>) S(-) amlodipine hemi D(-) tartarate mono DMSO solvate.
  • Example 5 S(-)amlodipine hemi D(-)tartarate mono DMSO solvate from RS amlodipine To a stirred solution of lOOgm (0.245 moles) of RS amlodipine in 250ml DMSO was added a solution of 9.2 gm (0.06 moles, 0.25 eq) of D(-) tartaric acid in 250 ml DMSO. The solid starts separating from clear solution within 5-10 mins.
  • Example 6 R(+) Amlodipine besylate from R(+) Amlodipine hemi L(+) Tartarate mono DMSO solvate 68.8gm (0.122 mole, 95.2 % de) R (+) amlodipine hemi L(+) tartarate mono DMSO solvate prepared as per example 2 was suspended in aqueous isopropanol (70ml L A: 250 ml distilled water) and a solution of benzene sulfonic acid (19.35 gm of 90% technical grade, 0.110 mole) in 150ml water was added.
  • aqueous isopropanol 70ml L A: 250 ml distilled water
  • Example 7 R(+) Amlodipine besylate from R(+) Amlodipine hemi L(+) Tartarate mono
  • Example 8 S(-) Amlodipine besylate from S(-) Amlodipine hemi D(-) Tartarate mono DMSO solvate 50 gm (0.089mole) of S (-) amlodipine hemi D (-) tartarate mono DMSO solvate prepared as per example 4 was suspended in aqueous isopropanol (70ml IP A: 150 ml distilled water) and a solution of benzene sulfonic acid (14.1 gm of 90% technical grade, 0.081 mole) in 100ml water was added.
  • IP A 150 ml distilled water
  • DMSO solvate 50 gm (0.089mole) of S(-)amlodipine hemi D(-) tartarate mono DMSO solvate prepared as per example 4 was suspended in aqueous isopropanol (70ml EPA: 150 ml distilled water) and a solution of benzene sulfonic acid (15.47 gm of 90% technical grade, 0.089 mole) in 100ml water was added. The reaction mixture was stirred for 2 hrs and the slurry was filtered, washed with distilled water, hexane, the solid was dried under vac. at 40°C till constant weight to give S(-) amlodipine besylate (50.1 gm, 92.1 % yield) 99.3 ee by chiral
  • Example 10 S(-) Amlodipine besylate from S(-) Amlodipine hemi D(-) Tartarate mono DMSO solvate 50 gm (0.089mole) of S(-)amlodipine hemi D(-) tartarate mono DMSO solvate prepared as per example 4 was slurried in 200ml distilled water and solution of benzene sulfonic acid (15.47 gm of 90% technical grade, 0.089 mole) in 125ml water was added. The reaction mixture was stirred for 2 hrs and the slurry was filtered, washed with distilled water, hexane, the solid was dried under vac. at 40°C till constant weight to give S(-) amlodipine besylate (50.1 gm, 92.1 % yield) 99.3 ee by chiral HPLC.
  • Example 11 R(+) Amlodipine besylate from R(+) Amlodipine hemi L(+) Tartarate mono DMSO solvate 68.8 gm (0.122 mole, 95.2 % de) R (+) Amlodipine hemi L (+) tartarate mono DMSO solvate prepared as per example 1 was suspended in aqueous isopropanol (90ml LPA: 250 ml distilled water) and a solution of benzene sulfonic acid (19.35 gm of 90% technical grade,
  • Example 12 S(-) amlodipine maleate from S(-) amlodipine hemi D(-)-tartarate mono

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A process for the preparation of pharmaceutically acceptable salts of chiral Amlodipine namely S(-) Amlodipine and R(+) Amlodipine without isolation of the chiral free base wherein the product has optical purity ranging between 96-99% is described in the present invention. The process comprises resolving RS amlodipine base using L(+) or D(-) tartaric acid followed by reaction of the separated tartrate salt with an organic acid to obtain the salt corresponding to the acid used in ee ranging from 96-99%.

Description

PROCESS FOR PREPARATION OF CHIRAL AMLODIPINE SALTS Field of the invention The present invention relates to an improved process for the preparation of chiral amlodipine salts. More particularly, the present invention relates to the a process for the preparation of pharmaceutically acceptable salts of S (-) Amlodipine having formula (1) and R(+) Amlodipine having formula (2) wherein R= benzenesulphoinic acid, succinic acid, maleic acid, oxalic acid, p-toluene sulphonic acid as given hereinbelo in the presence of dimethylsulfoxide and their direct conversion to besylate without isolating free base.
FORMULA-1 FORMULA-2 Background of the invention Of all the salts of S (-) Amlodipine mentioned above, S (-) Amlodipine besylate (4-S)- 2- { [(2-aminoethyl)oxy]methyl) -4-(2-chlorophenyl)-6-methyl- 1 ,4-dihydropyridine-3 , 5 - dicarboxylate benzene sulfonate has commercial importance as a potent long acting calcium channel blocker. R(+) Amlodipine has been reported as a potent inhibitor of smooth muscle cell migration (PCT/EP-94/02697). (R, S) amlodipine and its salts are long acting calcium channel blockers and are useful for the treatment of cardiovascular disorders. Racemic amlodipine is currently being used for the treatment of hypertension and angina as a besylate salt. The preparation of racemic compound is described in EP 0089167. Amlodipine is racemic compound and has chiral center at 4 position of dihydropyridine ring. The S(-) isomer is having calcium channel blocker activity while R(+) isomer is a potent inhibitor of smooth muscle cell migration. Prior arts herein for the preparation of R and S enantiomers are a) resolution of amlodipine azide ester with optically active 2-methoxy-2-phenylethanol (J. Med. Chem. 29, 1696, 1986, EP appl. 0331315 A) or b) resolution of amlodipine base with optically active camphanic acid (J. Med. Chem. 35, 3341, 1992) c) resolution of R S amlodipine base with L (+) or D(-) tartaric acid respectively in organic solvent DMSO (USP 6,046,338 (2000) PCT95/25722 1995) d) resolution of penultimate azidoester precursor of amlodipine using cinchonidine. (USP 6,291, 490(2001), Chem. Pharm Bull. 28 (9), 2809- 2812, 1980). Preparation of S(-) amlodipine besylate has been disclosed in the publication (J. Chem. B., 693, 1997, 367-375, followed by folly described and claimed in out co-pending patent application no. NF347/02 which relates to the process for the preparation of pharmaceutically acceptable salts of S(-) Amlodipine such as besylate, succinate, maleate, oxalate and tosylate from S(-) Amlodipine. The main disadvantages of the prior art are: 1. The use of costly resolving agents like camphanic acid, 2-methoxy-2-phenylethanol, cinchonidine.
2. The use of 0.5 mole of L (+) or D(-) tartaric acid increasing the load of recovery of tartaric acid.
3. Low yield of isolated resolved salt using less quantities of resolving agent. 4. Use of large volumes of solvent (1:10)
5. Isolation of free chiral base from the salt and treatment with benzene sulfonic acid to get besylate salt. Objects of the invention The object of present invention is to provide a process for the preparation of S(-) and R(+) Amlodipine besylate frpom racemic amlodipine using D or L tartaric acid without isolating free amlodipine base Summary of the invention Accordingly, the present invention provides an improved process for the preparation of pharmaceutically acceptable chiral salts of Amlodipine namely S(-) Amlodipine salts having formula (1) and R(+) Amlodipine salts having formula (2)
FOR U A-1 FORMULA-2 wherein R is selected from the group consisting of benzenesulphoϊnic acid, succinic acid, maleic acid, oxalic acid and p-toluenesulphonicacid, wherein the salts of formula 1 and 2 are prepared without isolation of a free base with optical purity ranging between 96-99% the process comprising: (a) reacting a solution of RS amlodipine base in an organic solvent with a solution of L(+) or D(-) tartaric acid in an organic solvent at temperature ranging from 20-35°C for a period ranging between 16-24 hrs., to obtain a solvate comprising an amlodipine tartarate salt;
(b) separating and reacting the amlodipine tartarate salt obtained in step (a) with an aqueous solution of an acid optionally in presence of an organic solvent, and at a temperature ranging between 20-40°C;
(c) adding water to the reaction mixture of step (b) to obtain the salt of formula 1 or 2, separating the salt of formula 1 or 2 and drying to obtain salt corresponding to the acid used in step (2) with ee ranging from 96-99%. In one embodiment of the invention, the solvent used in step (a) is DMSO. In another embodiment of the invention, the concentration of RS amlodipine base to solvent (DMSO) ranges between 0.16 to 0.40 gm/ml. In yet another embodiment of the invention, L(+)-tartaric acid or D(-) tartaric acid employed is 0.25 mole equivalent of the amlodipine base. In a further embodiment of the invention, the solvate obtained in step (a) is a precipitate comprising S(-) Amlodipine hemi D(-) tartarate mono DMSO solvate or R(+) amlodipine hemi L(+) tartarate mono DMSO solvate. In another embodiment of the invention, the solvent used for salt formation in step (b) is selected from dimethylsulfoxide, isopropylacohol and ethanol. In another embodiment of the invention, the ratio of water to solvent cumulatively taken in steps (b) and (c) ranges between 5: 1 to 8: 1. In yet another embodiment of the invention, the acid used in step (b) is selected from the group consisting of benzenesulfonic, maleic, oxalic acid and p-toluene sulfonic acid. In another embodiment of the invention, the ratio of amlodipine tartarate salt to organic solvent in step (b) is in the range 1 : 1 to 1 : 5. In another embodiment of the invention, the mole equivalent of benzene sulfonic acid used ranges between 0.9 to 1. In another embodiment of the invention, the optical purity of R(+) amlodipine besylate or S(-) amlodipine besylate is improved from 95% to 99% . Detailed description of the invention The present invention provides a process for the preparation of pharmaceutically acceptable chiral Amlodipine salts comprising S(-) Amlodipine salts having formula (1) and R(+) Amlodipine salts having formula (2)
FORMULA-1 FORMULA-2 In the above formulae 1 and 2, R is selected from the group consisting of benzenesulphoinic acid, succinic acid, maleic acid, oxalic acid and p-toluene sulphonic acid. The salts of formula 1 and 2 are prepared without isolation of a free base with optical purity ranging between 96-99%. The process of the invention comprises of
(a) reacting the solution of RS amlodipine base in an organic solvent with a solution of L(+) or D(-) tartaric acid in an organic solvent at temperature ranging from 20-35°C for a period ranging between 16-24 hrs.
(b) separating the tartarate salt as obtained in step (a) and reacting the said salt with an aqueous solution of an acid optionally in presence of an organic solvent at a temperature ranging between 20-40°C.
(c) adding water to the reaction mixture as obtained in step (b) to obtain the salt, separating the salt and drying to obtain salt corresponding to the acid used in step (b) with ee ranging from 96-99%. The solvent used in step (a) above is preferably dimethyl sulfoxide (DMSO) and the concentration of the RS amlodipine base to solvent (DMSO) ranges between 0.16 to 0.40 gm/ml. The L(+)-tartaric acid or D(-) tartaric acid employed in step (a) is 0.25 mole equivalent of the base. The tartarate salt is obtained preferably by precipitation and the solvate precipitated is S(-) Amlodipine hemi D(-) tartarate mono DMSO solvate or R(+) amlodipine hemi L(+) tartarate mono DMSO solvate. The solvent used for salt formation in step (b) is selected from dimethylsulfoxide, isopropylacohol or ethanol. The ratio of amlodipine salt to organic solvent in step (b) is in the range 1:1 to 1:5 for salt formation. The ratio of water to solvent cumulatively taken in steps (b) and (c) ranges between 5:1 to 8:1. The acid used in step (b) is selected from benzenesulfonic acid, maleic acid, oxalic acid, and p-toluene sulfonic acid. The mole equivalent of benzene sulfonic acid used ranges between 0.9 to 1. The optical purity of R(+) amlodipine besylate or S(-) amlodipine besylate is improved from 95% to 99% The unique feature of the invention is production pf S(-) Amlodipine or R(+) amlodipine salts with high enantiomeric purity, in good yields (87-92%) with the quality required for preparation of pharmaceutical composition i.e. tablet formulation. The process of resolution of R,S amlodipine and besylate formation is shown in the scheme below:
L(+) TA Benzene DMSO - - , R(+) , A ,mlodipine besylate R,S-Amlodipine D(-) TA CA A , j. . , . Benzene DMSO_ S(-) Amlodιpme D(-) sulfonic^ S(-) Amlodipine • Tartaric acid mono — ^ *~ besylate DMSO salts The process of the present invention is described herein below with reference to examples, which are illustrative and should not be construed to limit the scope of the present invention in any manner. Optical purity (enantiomeric excess e.e.) was determined using chiral HPLC column:
Chiral Chrompak 15 cm, ultron, The mobile phase used disodiumhydrogen phosphate buffer pH 6.9: acetonitrile (80:20) with flow rate lml/min at 360 nm Rt-R=6.1 min., S=7.3 min. Example 1: R (+) Amlodipine hemi L(+)tartarate mono DMSO solvate from RS amlodipine To stirred solution of 10.50 gm (0.0256mole) of RS amlodipine in 30ml DMSO was added a solution of 1.93gm (0.128 moles, 0.5 eq.) of L(+) tartaric acid in 30 ml DMSO. The solid starts separating from clear solution within 5-10 ins. This was stirred for 3 hrs and solid was filtered off, washed with acetone and dried to give 6.66 gm (46.2%) R(+) amlodipine hemi L(+) tartarate mono DMSO solvate. mp. 160-162°C, 95.2% d.e. by chiral HPLC [J.Chrom. B. 693,367,(1997), J. Luksa, Dj. Josic, B. Podobric, B. Furlan, M.Kremser.] Example 2: R(+)AmIodipine hemiL(+) tartarate mono DMSO solvate from RS amlodipine To a stirred solution of lOOgm (0.245 moles) of RS amlodipine in 300ml DMSO was added a solution of 9.2 gm (0.06 moles, 0.25 eq) of L(+) tartaric acid in 300 ml DMSO. The solid starts separating from clear solution within 5-10 mins. This was stirred for 3 hrs and solid was filtered off, washed with acetone and dried to give 52.3gm (36.2%) R(+) amlodipine hemi L(+) tartarate mono DMSO solvate. mp. 160-162°C, 98.2%d.e. by chiral HPLC. Example 3: R(+)Amlodipine hemiL(+)tartarate mono DMSO solvate from RS amlodipine To a stirred solution of lOOgm (0.245 moles) of RS amlodipine in 150ml DMSO was added a solution of 9.2gm (0.06 moles, 0.25 eq) of L (+) tartaric acid in 100 ml DMSO. The solid starts separating from clear solution within 5-10 mins. This was stirred for 3 hrs and solid was filtered off, washed with acetone and dried to give 58.6gm (40.5%) R (+) amlodipine hemi L(+) tartarate mono DMSO solvate. mp. 160-162°C,96.8 %d.e. by chiral HPLC.
Example 4: S(-)amIodipine hemi D(-)tartarate mono DMSO solvate from RS amlodipine To a stirred solution of lOOgm (0.245 moles) of RS amlodipine in 500ml DMSO was added a solution of 9.2 gm (0.06 moles, 0.25 eq) of D(-) tartaric acid in 500 ml DMSO. The sohd starts separating from clear solution within 5-10 mins. This was stirred at room temperature overnight and sohd was filtered off, washed with acetone and dried to give 47.5gm (34.6%>) S(-) amlodipine hemi D(-) tartarate mono DMSO solvate. mp. 159-161°C, 99.5%d.e. by chiral HPLC. Example 5: S(-)amlodipine hemi D(-)tartarate mono DMSO solvate from RS amlodipine To a stirred solution of lOOgm (0.245 moles) of RS amlodipine in 250ml DMSO was added a solution of 9.2 gm (0.06 moles, 0.25 eq) of D(-) tartaric acid in 250 ml DMSO. The solid starts separating from clear solution within 5-10 mins. This was stirred at room temperature overnight and solid was filtered off, washed with acetone and dried to give 56.2 gm (40.8 %) S (-) amlodipine hemi D(-) tartarate mono DMSO solvate. mp. 159-161°C, 98.4% d.e. by chiral HPLC.
Example 6: R(+) Amlodipine besylate from R(+) Amlodipine hemi L(+) Tartarate mono DMSO solvate 68.8gm (0.122 mole, 95.2 % de) R (+) amlodipine hemi L(+) tartarate mono DMSO solvate prepared as per example 2 was suspended in aqueous isopropanol (70ml L A: 250 ml distilled water) and a solution of benzene sulfonic acid (19.35 gm of 90% technical grade, 0.110 mole) in 150ml water was added. The reaction mixture was stirred for 2 hrs and the slurry was filtered, washed with distilled water, hexane, the solid was dried under vac. at 40°C till constant weight to give R(+) amlodipine besylate (63.4 gm, 84.6 % yield) 99.3 ee by chiral HPLC.
Microanalysis: C 51.33 %, H 6.13 %, N 4.62%, S 5.51 Calc. For C20H24O5N2C1
C6H6O3S.2.5 (H2O) C 51.1%, H 5.7%, N 4.58%, S 5.24 %. Example 7: R(+) Amlodipine besylate from R(+) Amlodipine hemi L(+) Tartarate mono
DMSO solvate 68.8gm (0.122 mole, 95.2 % de) R (+) amlodipine hemi L(+) tartarate mono DMSO solvate prepared as per example-2 was suspended in aqueous isopropanol (70ml IP A: 250 ml distilled water) and a solution of benzene sulfonic acid (21.28 gm of 90% technical grade, 0.122 mole) in 150ml water was added. The reaction mixture was stirred for 2 hrs and the slurry was filtered, washed with distilled water, hexane, the sohd was dried under vac. at
40°C till constant weight to give R(+) amlodipine besylate (66.74 gm, 89.1 % yield) 98.7 ee by chiral HPLC.
Example 8: S(-) Amlodipine besylate from S(-) Amlodipine hemi D(-) Tartarate mono DMSO solvate 50 gm (0.089mole) of S (-) amlodipine hemi D (-) tartarate mono DMSO solvate prepared as per example 4 was suspended in aqueous isopropanol (70ml IP A: 150 ml distilled water) and a solution of benzene sulfonic acid (14.1 gm of 90% technical grade, 0.081 mole) in 100ml water was added. The reaction mixture was stirred for 2 hrs and the slurry was filtered, washed with distilled water, hexane, the sohd was dried under vac. at 40°C till constant weight to give S (-) amlodipine besylate (47.5 gm, 87.2 % yield) 99.5 ee by chiral
HPLC.
Microanalysis: C 50.91 %, H 6.3 %, N 4.67%, S 5.91 Calc. For C20H24O5N2C1
C6H6O3S.2.5 (H2O) C 51.1%, H 5.7%, N 4.58%, S 5.24 %. Example 9: S(-) Amlodipine besylate from S(-) Amlodipine hemi D(-) Tartarate mono
DMSO solvate 50 gm (0.089mole) of S(-)amlodipine hemi D(-) tartarate mono DMSO solvate prepared as per example 4 was suspended in aqueous isopropanol (70ml EPA: 150 ml distilled water) and a solution of benzene sulfonic acid (15.47 gm of 90% technical grade, 0.089 mole) in 100ml water was added. The reaction mixture was stirred for 2 hrs and the slurry was filtered, washed with distilled water, hexane, the solid was dried under vac. at 40°C till constant weight to give S(-) amlodipine besylate (50.1 gm, 92.1 % yield) 99.3 ee by chiral
HPLC. Example 10: S(-) Amlodipine besylate from S(-) Amlodipine hemi D(-) Tartarate mono DMSO solvate 50 gm (0.089mole) of S(-)amlodipine hemi D(-) tartarate mono DMSO solvate prepared as per example 4 was slurried in 200ml distilled water and solution of benzene sulfonic acid (15.47 gm of 90% technical grade, 0.089 mole) in 125ml water was added. The reaction mixture was stirred for 2 hrs and the slurry was filtered, washed with distilled water, hexane, the solid was dried under vac. at 40°C till constant weight to give S(-) amlodipine besylate (50.1 gm, 92.1 % yield) 99.3 ee by chiral HPLC.
Example 11: R(+) Amlodipine besylate from R(+) Amlodipine hemi L(+) Tartarate mono DMSO solvate 68.8 gm (0.122 mole, 95.2 % de) R (+) Amlodipine hemi L (+) tartarate mono DMSO solvate prepared as per example 1 was suspended in aqueous isopropanol (90ml LPA: 250 ml distilled water) and a solution of benzene sulfonic acid (19.35 gm of 90% technical grade,
0.110 mole) in 150ml water was added. The reaction mixture was stirred for 2 hrs and the slurry was filtered, washed with distilled water, hexane, the solid was dried under vac. at
40°C till constant weight to give R(+) amlodipine besylate (51.6 gm, 69.4 % yield) 99.3 ee by chiral HPLC.
Example 12: S(-) amlodipine maleate from S(-) amlodipine hemi D(-)-tartarate mono
DMSO solvate S(-) amlodipine hemi D(-)-tartarate mono DMSO solvate (6.8 gm, 0.012 moles) was dissolved in ethanol (10 ml) and maleic acid (1.42 gms 0.012 moles) in 70 ml of water was added with stirring. The separated solid was filtered washed with cold water, washed with hexane and dried under vacuo to give 5.32 gms (82.88%) of S(-) amlodipine maleate, mp.
176-177°C Optical rotation [αT/D = -25.10 (c=l, MeOH) 98.31 ee. Example 13: S(-) amlodipine oxalate from S(-) amlodipine hemi D(-)-tartarate mono
DMSO solvate S(-) amlodipine hemi D(-)-tartarate mono DMSO solvate (6.8 gm, 0.012 moles) was dissolved in ethanol (10 ml) and oxalic acid (1.54 gms 0.012 moles) in 70 ml of water was added with stirring. The separated solid was filtered washed with cold water, washed with hexane and dried under vacuo to give 5.80 gms (89.2%) of S(-) amlodipine oxalate, mp. 201-
203°C Optical rotation [αT/D = -27.95 (c=l, MeOH) 98.41 ee.
Advantages of the invention:
1. Use of costly resolving agents like camphanic acid, 2-methoxy-2-phenylethanol, cinchonidine is avoided. 2. The use of 0.5 mole of L (+) or D(-) tartaric acid increasing the load of recovery of tartaric acid is avoided.
3. The yield of isolated resolved salt using less quantities of resolving agent is high.
4. The use of large volumes of solvent ( 1 : 10) is avoided.
5. The isolation of free chiral base from the salt and treatment with benzene sulfonic acid to get besylate salt is avoided.

Claims

We claim:
• 1. A process for the preparation of pharmaceutically acceptable chiral salts of Amlodipine namely S(-) Amlodipine salts having formula (1) and R(+) Amlodipine salts having formula (2)
FORMULA-1 FORMULA-2 wherein R is selected from the group consisting of benzenesulphoinic acid, succinic acid, maleic acid, oxalic acid and p-toluenesulphonicacid, wherein the salts of formula 1 and 2 are prepared without isolation of a free base with optical purity ranging between 96-99% the process comprising: (a) reacting a solution of RS amlodipine base in an organic solvent with a solution of L(+) or D(-) tartaric acid in an organic solvent at temperature ranging from 20-35°C for a period ranging between 16-24 hrs., to obtain a solvate comprising an amlodipine tartarate salt; (b) separating and reacting the amlodipine tartarate salt obtained in step (a) with an aqueous solution of an acid optionally in presence of an organic solvent, and at a temperature ranging between 20-40°C; (c) adding water to the reaction mixture of step (b) to obtain the salt of formula 1 and 2, separating the salt of formula 1 and 2 and drying to obtain salt corresponding to the acid used in step (2) with ee ranging from 96-99%).
2. A process as claimed in claim 1 wherein the solvent used in step (a) is DMSO.
3. A process as claimed in claim 1 wherein the concentration of RS amlodipine base to solvent (DMSO) ranges between 0.16 to 0.40 gm/ml.
4. A process as claimed in claim 1 wherein the L(+)-tartaric acid or D(-) tartaric acid employed is 0.25 mole equivalent of the amlodipine base.
5. A process as claimed in claim 1 wherein the solvate obtained in step (a) is a precipitate comprising S(-) Amlodipine hemi D(-) tartarate mono DMSO solvate or R(+) amlodipine hemi L(+) tartarate mono DMSO solvate.
6. A process as claimed in claim 1 wherein the solvent used for salt formation in step (b) is selected from dimethylsulfoxide, isopropylacohol and ethanol.
7. A process as claimed in claim 1 wherein the cumulative ratio of water to solvent in steps (b) and (c) ranges between 5:1 to 8:1.
8. A process as claimed in claim 1 wherein the acid used in step (b) is selected from the group consisting of benzenesulfonic, maleic, oxalic acid and p-toluene sulfonic acid.
9. A process as claimed in claim 1 wherein the ratio of amlodipine tartarate salt to organic solvent in step (b) is in the range 1:1 to 1:5.
10. A process as claimed in claim 8 wherein the mole equivalent of benzene sulfonic acid used ranges between 0.9 to 1.
11. A process as claimed in claim 1 wherein the optical purity of R(+) amlodipine besylate or S(-) amlodipine besylate is improved from 95% to 99% .
EP04791865A 2003-11-20 2004-10-19 Process for preparation of chiral amlodipine salts Withdrawn EP1687273A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1440DE2003 2003-11-20
PCT/IN2004/000324 WO2005049571A1 (en) 2003-11-20 2004-10-19 Process for preparation of chiral amlodipine salts

Publications (1)

Publication Number Publication Date
EP1687273A1 true EP1687273A1 (en) 2006-08-09

Family

ID=34611190

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04791865A Withdrawn EP1687273A1 (en) 2003-11-20 2004-10-19 Process for preparation of chiral amlodipine salts

Country Status (5)

Country Link
EP (1) EP1687273A1 (en)
KR (1) KR20060086432A (en)
CN (1) CN1882543A (en)
BR (1) BRPI0416648A2 (en)
WO (1) WO2005049571A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1802576E (en) * 2004-10-20 2008-09-15 Emcure Pharmaceuticals Ltd Process for producing enantiomer of amlodipine in high optical purity
KR101235116B1 (en) * 2005-10-17 2013-02-20 에스케이케미칼주식회사 Process for preparation of chiral amlodipine gentisate
KR100843400B1 (en) * 2006-11-14 2008-07-04 씨제이제일제당 (주) Crystalline S---amlodipine maleic acid salt anhydrous and preparation method thereof
CN101468986B (en) * 2007-12-26 2010-12-29 香港南北兄弟国际投资有限公司 Method for splitting dihydropyrimidine racemic compound
KR100979772B1 (en) * 2008-06-12 2010-09-02 에이치 엘 지노믹스(주) Process for preparing optically pure S---amlodipine benzensulfonate
KR101313842B1 (en) * 2010-09-15 2013-10-01 대화제약 주식회사 A manufacturing method of esamlodipine besilate and its hydrate
CN102516159B (en) * 2011-12-15 2013-10-09 扬子江药业集团江苏海慈生物药业有限公司 Method for producing S-(-)-amlodipine besylate
CN104592099A (en) * 2014-12-30 2015-05-06 山东鲁抗医药股份有限公司 Refining method for improving optical purity of levoamlodipine besylate
CN111689894B (en) * 2019-03-13 2023-05-02 鲁南制药集团股份有限公司 Levamlodipine besylate crystal form
CN112110850B (en) * 2019-06-20 2023-05-02 鲁南制药集团股份有限公司 Novel crystal form of levamlodipine besylate
CN116332832A (en) * 2023-03-29 2023-06-27 安徽美致诚药业有限公司 Maleic acid levo-amlodipine amorphous crystal form and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405833D0 (en) * 1994-03-24 1994-05-11 Pfizer Ltd Separation of the enantiomers of amlodipine
DE60112305T2 (en) * 2000-12-29 2006-05-24 Pfizer Ltd., Sandwich PROCESS FOR PREPARING AMLODIPINMALEAT
US6608206B1 (en) * 2002-10-30 2003-08-19 Council Of Scientific & Industrial Research Process for making S(-) Amlodipine salts

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2005049571A1 *

Also Published As

Publication number Publication date
KR20060086432A (en) 2006-07-31
WO2005049571A1 (en) 2005-06-02
CN1882543A (en) 2006-12-20
BRPI0416648A2 (en) 2009-01-13

Similar Documents

Publication Publication Date Title
EP2133330B1 (en) Atropisomer of pyrrole derivative
WO2005049571A1 (en) Process for preparation of chiral amlodipine salts
EP1831166B1 (en) Optical resolution method of amlodipine
US6608206B1 (en) Process for making S(-) Amlodipine salts
WO2001060799A1 (en) Resolution of the enantiomers of amlodipine
CN101316820B (en) Process for preparation of chiral amlodipine gentisate
US6846932B1 (en) Process for preparation of chiral amlodipine salts
JPH0772186B2 (en) Flavone derivative, production method thereof, and medicament containing the same
ZA200205223B (en) Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same.
EP1407773A1 (en) A process for the preparation of s (-) amlodipine salts
ZA200402059B (en) Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same.
NZ204536A (en) 1,4-dihydropyridine derivatives and pharmaceutical compositions
US20090227800A1 (en) novel process for the preparation of lercanidipine
US7148358B2 (en) Process for the preparation of S(−) amlodipine-L(+)-hemi taratarte
AU778306B2 (en) Phenyl- and pyridyl-tetrahydro-pyridines having TNF inhibiting activity
EP1348697A1 (en) Process for the preparation of S(-)-amlodipine-L(+)-hemitartrate
CA2361758A1 (en) Process for the production of paroxetine
KR101085169B1 (en) Process for separating the enantiomers of amlodipine
WO2010068049A2 (en) Process for preparing (r)-(+)-lansoprazole and intermediate used therein
WO2005054196A1 (en) A Method for the Enantiomoeric Separation of Optical Active Amlodipine
CN115819171A (en) Chiral resolution method of key intermediate in MOR receptor agonist synthetic route
FI83516B (en) Process for the preparation of pharmacologically valuable 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5- dicarboxylic acid-3-(1-benzylpyrrolidine-3-yl)-ester-5- methylester's A-diastereoisomer
CN110885315A (en) Preparation method of important intermediate of levosimendan
WO2010027113A2 (en) Process for preparing (s)-(-)-felodipine
JP2010518155A (en) Method for producing S-(-)-amlodipine or a salt thereof and intermediate used therefor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060531

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

17Q First examination report despatched

Effective date: 20061123

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070404